Scarica l'app Stockscreener
7.94
2.34%
-0.19
Dopo l'orario di chiusura:
7.97
0.03
+0.38%
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - The Globe and Mail
Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Trendlines Converge — Decision Point for The Ruby Mills LimitedAnalyst Downgrades & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kyverna’s Autoimmune CAR T Bet Rides On 2025–26 Trial Readouts - Finimize
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stockSan Francisco Business Times - The Business Journals
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why - The Globe and Mail
Twin Insider Buys Signal Major Confidence in Kyverna Therapeutics - TipRanks
Kyverna Therapeutics (NASDAQ:KYTX) Major Shareholder Biopartners Opportuni Westlake Purchases 133,333 Shares - MarketBeat
Beth Seidenberg Purchases 133,333 Shares of Kyverna Therapeutics (NASDAQ:KYTX) Stock - MarketBeat
Kyverna Therapeutics director Seidenberg buys $999,997 in shares By Investing.com - Investing.com Nigeria
Westlake BioPartners buys Kyverna Therapeutics (KYTX) shares worth $999,997 By Investing.com - Investing.com Australia
Kyverna Therapeutics director Seidenberg buys $999,997 in shares - Investing.com
Westlake BioPartners buys Kyverna Therapeutics (KYTX) shares worth $999,997 - Investing.com
Kyverna Therapeutics Insider Bought Shares Worth $999,998, According to a Recent SEC Filing - marketscreener.com
William Blair Initiates Coverage of Kyverna Therapeutics (KYTX) with Outperform Recommendation - MSN
Kyverna Therapeutics (KYTX) Price Target Increased by 11.68% to 28.76 - Nasdaq
Will Kyverna Therapeutics Inc. stock recover faster than peers2025 EndofYear Setup & Verified Swing Trading Watchlists - Улправда
Institution Moves: What margin trends mean for Kyverna Therapeutics Inc. stockForecast Cut & Community Trade Idea Sharing - ulpravda.ru
Why Kyverna Therapeutics Inc. stock is rated strong buy2025 Market Outlook & Weekly Stock Breakout Alerts - Улправда
Kyverna Therapeutics Inc. (KYTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
EPS Watch: Is Kyverna Therapeutics Inc. stock attractive after correction2025 Momentum Check & Fast Gaining Stock Reports - Улправда
Market Leaders: What margin trends mean for Kyverna Therapeutics Inc. stockJuly 2025 Pullbacks & Accurate Buy Signal Alerts - ulpravda.ru
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Is Kyverna Therapeutics Inc. stock near bottom after declineGDP Growth & Growth Focused Stock Pick Reports - DonanımHaber
Kyverna Therapeutics announces $100 million public offering - MSN
Is Kyverna Therapeutics Inc. stock attractive after correctionDollar Strength & Daily Stock Trend Reports - ulpravda.ru
What is the fair value of Kyverna Therapeutics Inc. stock nowMarket Volume Summary & Real-Time Market Sentiment Alerts - DonanımHaber
Will Kyverna Therapeutics Inc. stock see PE expansionQuarterly Growth Report & Fast Moving Trade Plans - DonanımHaber
Aug PostEarnings: How buybacks impact Kyverna Therapeutics Inc. stock valueJuly 2025 Highlights & High Accuracy Investment Signals - ulpravda.ru
What margin trends mean for Kyverna Therapeutics Inc. stockJuly 2025 Earnings & High Yield Equity Trading Tips - Улправда
How buybacks impact Kyverna Therapeutics Inc. stock valueJuly 2025 Snapshot & Low Risk High Win Rate Picks - ulpravda.ru
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies (NASDAQ:KYTX) - Seeking Alpha
Kyverna Therapeutics (KYTX) Valuation After Positive KYSA-8 CAR T Data and First-in-Class Prospects - Yahoo Finance
Kyverna Therapeutics Announces $100 Million Public Offering - TipRanks
Kyverna Therapeutics Signs Underwriting Agreement With J.P. Morgan, Leerink Partners and Morgan Stanley - TradingView — Track All Markets
Kyverna Therapeutics (NASDAQ:KYTX) CTO Karen Marie Walker Sells 23,998 Shares - MarketBeat
Kyverna Therapeutics CTO Karen Marie Walker Sells Shares - TradingView — Track All Markets
Officer Walker Sells 23,998 ($292.8K) Of Kyverna Therapeutics Inc [KYTX] - TradingView — Track All Markets
Kyverna Therapeutics Shares Drop After Public Offering - StocksToTrade
Kyverna Therapeutics stock plunges after $100 million share offering By Investing.com - Investing.com Nigeria
Kyverna Therapeutics stock plunges after $100 million share offering - Investing.com India
Transcript : Kyverna Therapeutics, Inc.Special Call - marketscreener.com
Kyverna Therapeutics announces pricing of $100M public offering - MSN
Kyverna Therapeutics prices public offering of common stock at $7.50 - Investing.com
Kyverna Therapeutics Prices $100 Million Common Stock Offering - marketscreener.com
Kyverna Therapeutics announces pricing of $100 million public offering - marketscreener.com
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):